Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment.
نویسندگان
چکیده
منابع مشابه
rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precur-
controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20: 2486-94. 12. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B. Onceweekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003, in press. 13. Pangalis GA, Sia...
متن کاملThe Efficacy of Recombinant Human Erythropoietin in Treatment Chemotherapy Induced Anemia in Children Diagnosed with a Solid Cancer
Background Recombinant human erythropoietin (rHuEPO) treatment can increase hemoglobin levels and decrease transfusion requirements. This study aims to investigate how blood transfusion influences Hemoglobin levels in patients receiving rHuEPO for 12 weeks. Materials and Methods This was a case-control study of 60 patients less than 15 years with anemia and a solid tumor in any location betw...
متن کاملEffects of Recombinant Human Erythropoietin Pretreatment on Anti-HLA Antibody Titer: A Preclinical Experience in Rats
Background: Erythropoietin (EPO) was first known as a factor for red blood cell proliferation and differentiation. New studies show the effects of EPO on immune system. Objective: In this study, the effects of pretreatment with recombinant human erythropoietin (rHuEPO) on the anti-human leukocyte antibody (anti-HLA) titer were determined. Methods: Three groups of rats were sensitized with human...
متن کاملEfficacy of lenalidomide in myelodysplastic syndromes.
BACKGROUND Ineffective erythropoiesis is the hallmark of myelodysplastic syndromes. Management of the anemia caused by ineffective erythropoiesis is difficult. In patients with myelodysplastic syndromes and symptomatic anemia, we evaluated the safety and hematologic activity of lenalidomide, a novel analogue of thalidomide. METHODS Forty-three patients with transfusion-dependent or symptomati...
متن کاملPHARMA COKINETICS OF RECOMBINANT ERYTHROPOIETIN AND RED CELL METABOLISM IN HAEMODIALYSIS PATIENTS
The pharmacokinetics of recombinant human erythropoietin (rHuEpo) administered intravenously has been investigated in a group of five patients with chronic renal failure who were dialysis-dependent. The half-life of circulating erythropoietin decreased from 7.9±OA hr (mean ±SO) at the beginning of treatment to 6.2±O.6 hr after 6 weeks and 5A±O.9 hr after 4 months of treatment. In spite of t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Haematologica
دوره 95 2 شماره
صفحات -
تاریخ انتشار 2010